All lobbying filings

WILLIAMS AND JENSEN, PLLC

Lobbying for ELI LILLY & COMPANY · Pharmaceutical/ Health Products

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · District of Columbia · House · Senate · $50,000.00 income · posted Jul 20, 2026

Official filing document

Bills named in this filing 1

HR 6509
SAFE Drugs Act of 2025

Lobbying activity 7

Pharmacy

Drug importation, prescription drug safety, value and access.

Taxation/Internal Revenue Code

International and domestic tax issues. Implementation of PL 119-21.

Health Issues

340B Drug Pricing program, pharmaceutical supply chain, drug compounding and counterfeiting issues, PBM reform policies. SAFE Drugs Act (HR6509/S3794).

Medicare/Medicaid

Issues related to drug pricing; Issues related to reimbursement of insulin products and obesity medications: Issues related to the One Big Beautiful Bill Act (PL 119-21), most favored nation pricing polices.

Budget/Appropriations

Accelerated approval pathway; support for Alzheimer's diagnostics; obesity treatment.

Trade (domestic/foreign)

Monitor Issues related to intellectual property protection and market access within current trade negotiations. Section 232 investigations and other tariff issues. Pharmaceutical IP issues, march-in rights.

Defense

Issues related to pharmaceutical manufacturing and development.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.